Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 18/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL98281 | 1.00 | CHRM3 (0.55) | CHRM3CHRM2CHRM1CHRM5HTR2C | |
| SCHEMBL98785 | 0.90 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM5HTR2C | |
| SCHEMBL100251 | 0.90 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM5HTR2C | |
| SCHEMBL98784 | 0.90 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM5HTR2C | |
| SCHEMBL100252 | 0.90 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM5HTR2C | |
| SCHEMBL97809 | 0.88 | CHRM3 (0.59) | CHRM3 | |
| SCHEMBL130787 | 0.88 | CHRM3 (0.57) | CHRM3CHRM2CHRM1CHRM5MEN1 | |
| SCHEMBL98847 | 0.86 | CHRM3 (0.58) | CHRM3 | |
| SCHEMBL132125 | 0.85 | CHRM3 (0.56) | CHRM3CHRM2CHRM1CHRM5MEN1 | |
| SCHEMBL131856 | 0.81 | CHRM3 (0.47) | CHRM3CHRM2CHRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9072734-B2 | Quaternary ammonium salt compounds | TEIJIN PHARMA LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| EP-2426121-A1 | QUATERNARY AMMONIUM SALT COMPOUND | Teijin Pharma Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | TEIJIN PHARMA LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | ADRB2, AGTR2, ADRB3 | CHRM3 9/4885CHRM2 15/4885CHRM1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.